We are live on ! Find out more
AGN

Allergan plc
AGN

Delisted

AGN was delisted on the 8th of May, 2020.

1,043 hedge funds and large institutions have $44.4B invested in Allergan plc in 2018 Q2 according to their latest regulatory filings, with 110 funds opening new positions, 366 increasing their positions, 425 reducing their positions, and 83 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 110 | Existing positions closed: 83

2% more funds holding

Funds holding: 1,0221,043 (+21)

0% more funds holding in top 10

Funds holding in top 10: 4545 (0)

3% less capital invested

Capital invested by funds: $45.8B → $44.4B (-$1.36B)

14% less repeat investments, than reductions

Existing positions increased: 366 | Existing positions reduced: 425

29% less call options, than puts

Call options by funds: $990M | Put options by funds: $1.39B

Holders
1,043
Holders Change
+21
Holders Change %
+2.05%
% of All Funds
23.79%
Holding in Top 10
45
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
1.03%
New
110
Increased
366
Reduced
425
Closed
83
Calls
$990M
Puts
$1.39B
Net Calls
-$399M
Net Calls Change
+$189M

AGN Hedge Fund Activity: Q2 2018 in Review

1,043 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Allergan plc (AGN) for Q2 2018, worth a combined $44.4B — down 3% from $45.8B a quarter earlier.

Buyers outnumbered sellers: 110 funds opened new AGN positions and 83 closed out — a net gain of 27 holders — while 366 added to existing stakes and 425 trimmed.

The largest buyer was King Street Capital Management, opening a new position worth an estimated $174M. The largest seller was Jackson Square Partners, exiting entirely with an estimated $336M sold.

  • 1,043 institutional investors held Allergan plc (AGN) as of Q2 2018, up from 1,022 in Q1 2018.
  • Funds reported $44.4B of Allergan plc stock for Q2 2018, down 3% quarter-over-quarter.
  • 110 funds opened new Allergan plc positions in Q2 2018 and 83 closed out, a net change of +27 holders.
  • The largest Allergan plc buyer in Q2 2018 was King Street Capital Management, an estimated $174M added.
  • The largest Allergan plc seller in Q2 2018 was Jackson Square Partners, an estimated $336M sold.

Based on aggregated 13F filings for Q2 2018.